The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Johnson & Johnson Hit with $500 Million Verdict in Trial over Hip Implants

Johnson & Johnson Hit with $500 Million Verdict in Trial over Hip Implants

March 17, 2016 • By Jessica Dye

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters)—Johnson & Johnson and its DePuy unit were ordered by a Texas federal jury on Thursday to pay a total of about $500 million to five plaintiffs who said they were injured by Pinnacle metal-on-metal hip implants.

You Might Also Like
  • U.S. Judge Cuts $500 Million Verdict over Johnson & Johnson Hip Implants
  • Verdict: Johnson & Johnson to Pay More Than $1 Billion for Defective Hip Implants
  • Zimmer Wins First U.S. Trial over NexGen Flex Knee Devices

Following a two-month trial, jurors found that the Pinnacle hips were defectively designed, and that the companies failed to warn the public about their risks.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Jurors awarded about $130 million in total compensatory damages and about $360 million in punitive damages, according to the plaintiffs’ lead trial lawyer, Mark Lanier.

“There are thousands of these cases, and J&J needs to get responsible,” Lanier said following the verdict, which came in the second federal trial involving the Pinnacle device.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

J&J was cleared of liability in the first trial ended in 2014.

A J&J spokeswoman said the company plans to appeal the verdict.

All five plaintiffs are Texas residents who were implanted with metal-on-metal Pinnacle hip devices. They said design flaws caused the devices to fail more frequently and quickly than expected, leading to injuries, including tissue death, bone erosion and high levels of metal in their blood.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Filed Under: Pharma Co. News Tagged With: hip, hip replacement, implant, Johnson & Johnson, lawsuit, Legal

You Might Also Like:
  • U.S. Judge Cuts $500 Million Verdict over Johnson & Johnson Hip Implants
  • Verdict: Johnson & Johnson to Pay More Than $1 Billion for Defective Hip Implants
  • Zimmer Wins First U.S. Trial over NexGen Flex Knee Devices
  • Johnson & Johnson Discloses U.S. Probe Related to Arthritis Drugs

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.